FLAIR JOSE CARRILHO

(Fonte: Lattes)
Índice h a partir de 2011
32
Lattes
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Gastroenterologia, Faculdade de Medicina - Docente
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/07 - Laboratório de Gastroenterologia Clínica e Experimental, Hospital das Clínicas, Faculdade de Medicina - Líder

Filtros

Mostrar mais
Limpar filtros

Configurações

search.filters.applied.f.dateIssued: 2019 ×

Resultados de Busca

Agora exibindo 1 - 10 de 23
  • article 5 Citação(ões) na Scopus
    A phenotypical map of disseminated hepatocellular carcinoma suggests clonal constraints in metastatic sites
    (2019) MARTINS-FILHO, Sebastiao N.; ALVES, Venancio A. F.; WAKAMATSU, Alda; MAEDA, Miho; CRAIG, Amanda J.; ASSATO, Aline K.; VILLACORTA-MARTIN, Carlos; D'AVOLA, Delia; LABGAA, Ismail; CARRILHO, Flair J.; THUNG, Swan N.; VILLANUEVA, Augusto
    Aims Access to tissue in patients with hepatocellular carcinoma (HCC) is limited compared to other malignancies, particularly at advanced stages. This has precluded a thorough characterisation of molecular drivers of HCC dissemination, particularly in relation to distant metastases. Biomarker assessment is restricted to early stages, and paired primary-metastatic comparisons between samples from the same patient are difficult. Methods and results We report the evaluation of 88 patients with HCC who underwent autopsy, including multiregional sampling of primary and metastatic sites totalling 230 nodules analysed. The study included morphological assessment, immunohistochemistry and mutation status of the TERT promoter, the most frequently mutated gene in HCC. We confirm a strong predilection of HCC for lung dissemination, including subclinical micrometastases (unrecognised during imaging and macroscopic examinations) in 30% of patients with disseminated disease. Size of dominant tumour nodule; multinodularity; macrovascular invasion; high histological, nuclear and architectural grades; and cellular crowding were associated with the presence of extrahepatic metastasis. Among the immunohistochemistry markers tested, metastatic nodules had significantly higher K19 and EpCAM expression than primary liver tumours. Morphological and immunohistochemical features showed that metastatic HCC could be traced back to the primary tumour, sometimes to a specific hepatic nodule. Conclusions This study suggests limited heterogeneity in metastatic sites compared to primary tumour sites.
  • article 28 Citação(ões) na Scopus
    Sofosbuvir inhibits yellow fever virus in vitro and in patients with acute liver failure
    (2019) MENDES, Erica Araujo; PILGER, Denise Regina Bairros de; NASTRI, Ana Catharina de Seixas Santos; MALTA, Fernanda de Mello; PASCOALINO, Bruno dos Santos; D'ALBUQUERQUE, Luiz Augusto Carneiro; BALAN, Andrea; JR, Lucio Holanda Gondim de Freitas; DURIGON, Edison Luis; CARRILHO, Flair Jose; PINHO, Joao Renato Rebello
    Introduction and objectives: Direct antiviral agents (DAAs) are very efficient in inhibiting hepatitis C virus and might be used to treat infections caused by other flaviviruses whose worldwide detection has recently increased. The aim of this study was to verify the efficacy of DAAs in inhibiting yellow fever virus (YFV) by using drug repositioning (a methodology applied in the pharmaceutical industry to identify new uses for approved drugs). Materials and methods: Three DAAs were evaluated: daclatasvir, sofosbuvir and ledipasvir or their combinations. For in vitro assays, the drugs were diluted in 100% dimethyl sulfoxide. Vaccine strain 17D and a 17D strain expressing the reporter fluorescent protein were used in the assays. A fast and reliable cell-based screening assay using Vero cells or Huh-7 cells (a hepatocyte-derived carcinoma ell line) was carried out. Two patients who acquired yellow fever virus with acute liver failure were treated with sofosbuvir for one week as a compassionate use. Results: Using a high-content screening assay, we verified that sofosbuvir presented the best antiviral activity against YFV. Moreover, after an off-label treatment with sofosbuvir, the two female patients diagnosed with yellow fever infection displayed a reduction in blood viremia and an improvement in the course of the disease, which was observed in the laboratory medical parameters related to disease evolution. Conclusions: Sofosbuvir may be used as an option for treatment against YFV until other drugs are identified and approved for human use. These results offer insights into the role of nonstructural protein 5 (NS5) in YFV inhibition and suggest that nonstructural proteins may be explored as drug targets for YFV treatment. (C) 2019 Fundacion Clinica Medica Sur, A.C.
  • conferenceObject
    FRESH FROZEN PLASMA TRANSFUSION IN PATIENTS WITH CIRRHOSIS AND COAGULOPATHY: EFFECT ON CONVENTIONAL COAGULATION TESTS AND THROMBOMODULIN-MODIFIED THROMBIN GENERATION
    (2019) RASSI, Amanda Bruder; D'AMICO, Elbio Antonio; TRIPODI, Armando; ROCHA, Tania Rubia Flores; MIGITA, Beatriz; FERREIRA, Caroline Marcondes; CARRILHO, Flair Jose; FARIAS, Alberto Q.
  • conferenceObject
    Distinctive molecular traits of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis
    (2019) TORRECILLA, Sara; PINYOL, Roser; WANG, Huan; MONTIRONI, Carla; ANDREU-OLLER, Carmen; LEOW, Wei Qiang; MOEINI, Agrin; OLIVEIRA, Claudia; ALVES, Venancio Avancini Ferreira; LACHENMAYER, Anja; ROESSLER, Stephanie; MINGUEZ, Beatriz; SCHIRMACHER, Peter; BOFFETTA, Paolo; DUFOUR, Jean-Francois; THUNG, Swan N.; UZILOV, Andrew; CARRILHO, Flair Jose; CHANG, Charissa; SIA, Daniela; LLOVET, Josep M.
  • conferenceObject
    TREATMENT WITH DIRECT-ACTING ANTIVIRALS (DAAS) NEITHER INCREASES THE RISK OF HEPATOCELLULAR CARCINOMA PROGRESSION DURING WAITING LIST NOR RECURRENCE AFTER LIVER TRANSPLANTATION
    (2019) PINERO, Federico; BOIN, Ilka; RUBINSTEIN, Fernando; CHAGAS, Aline; QUINONEZ, Emilio; MARCIANO, Sebastian; VILATOBA, Mario; VARON, Adriana; ANDERS, Margarita; DUQUE, Sergio Hoyos; LIMA, Agnaldo Soares; MENENDEZ, Josemaria; PADILLA, Martin; PONIACHICK, Jaime; ZAPATA, Rodrigo; BARRABINO, Martin; MENENDEZ, Ricardo Chong; MUNOZ, Linda; ARUFE, Diego; FIGUEROA, Rodrigo; MENDIZABAL, Manuel; ZANAGA, Leticia; MACCALI, Claudia; SANDOVAL, Rodrigo Vergara; BARMUDEZ, Carla; BELTRAN, Oscar; AENAS, Isabel; GERONA, Solange; IRACHETA, Alexis; GINESTA, Alexandra; GADANO, Adrian; MATTERA, Juan; STUCCHI, Raquel; CARRILLO, Flair; SILVA, Mauricio
  • article 18 Citação(ões) na Scopus
    Sorafenib for Treatment of Hepatocellular Carcinoma A Survival Analysis From the South American Liver Research Network
    (2019) LEATHERS, James S.; BALDERRAMO, Domingo; PRIETO, John; DIEHL, Fernando; GONZALEZ-BALLERGA, Esteban; FERREIRO, Melina R.; CARRERA, Enrique; BARREYRO, Fernando; DIAZ-FERRER, Javier; SINGH, Dupinder; MATTOS, Angelo Z.; CARRILHO, Flair; DEBES, Jose D.
    Goals: We aim to describe the efficacy, safety profile, and variables associated with survival in patients with hepatocellular carcinoma (HCC) treated with sorafenib in South America. Background: Sorafenib has been shown to improve survival in patients with advanced HCC. There are few data on sorafenib use for HCC in South America. Study: We performed a retrospective analysis of HCC cases treated with sorafenib from 8 medical centers in 5 South American countries, between January 2010 and June 2017. The primary endpoint was overall survival (OS), which was defined as time from sorafenib initiation to death or last follow-up. Risk factors for decreased OS were assessed using Cox proportional hazard regression and log-rank tests. Results: Of 1336 evaluated patients, 127 were treated with sorafenib and were included in the study. The median age of individuals was 65 years (interquartile range, 55 to 71) and 70% were male individuals. Median OS in all patients was 8 months (interquartile range, 2 to 17). Variables associated with survival on multivariate analysis were platelets >/<250,000 mm(3) (2 vs. 8 mo, P=0.01) and Barcelona Clinic Liver Cancer (BCLC) stage (A/B, 13 vs. C/D, 6 mo; P=0.04). In a subanalysis of patients with BCLC stage C, platelets >/<250,000 mm(3) were also independently associated with survival (2 vs. 5.5 mo, P=0.03). Patients lived longer if they experienced any side effects from sorafenib use (11 vs. 2 mo, P=0.009). Patients who stopped sorafenib because of side effects had shorter survival compared with patients who were able to tolerate side effects and continue treatment (7.5 vs. 13 mo, P=0.01). Conclusions: Pretreatment elevation of platelets and advanced BCLC stage were independently associated with poor survival on sorafenib in a South American cohort.
  • conferenceObject
    Hepatic epithelioid hemangioendotelioma: An international multicenter study
    (2019) ZAMPARELLI, Marco Sanduzzi; RIMOLA, Jordi; MONTIRONI, Carla; NUNES, Vinicius; ALVES, Venancio Avancini Ferreira; SAPENA, Victor; FORNER, Alejandro; CARRILHO, Flair Jose; DIAZ, Alba; FUSTER, Carla; FERRER, Joana; FUSTER, Josep; AYUSO, Carmen; SOLE, Manel; BRUIX, Jordi; REIG, Maria
  • conferenceObject
    SOCIODEMOGRAPHIC CHARACTERISTICS OF PATIENTS THAT AFFECT THE ADHERENCE TO HEPATOCELLULAR CARCINOMA SCREENING
    (2019) CAMARGO, Cinira Cintra; CHAGAS, Aline; ALENCAR, Regiane Saraiva De Souza Mel; TANI, Claudia Megumi; SAUD, Lisa Rodrigues Da Cunha; VEZOZZO, Denise Paranagua; COSTA, Thaisa De Fatima Almeida; MACCALI, Claudia; PINTO, Paulo Victor Alves; HORVAT, Natally; CARRILHO, Flair J.
  • conferenceObject
    Molecular fingerprint of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis
    (2019) TORRECILLA, Sara; PINYOL, Roser; WANG, Huan; MONTIRONI, Carla; ANDREU-OLLER, Carmen; LEOW, Wei Qiang; MOEINI, Agrin; OLIVEIRA, Claudia; ALVES, Venancio Avancini Ferreira; LACHENMAYER, Anja; ROESSLER, Stephanie; MINGUEZ, Beatriz; SCHIRMACHER, Peter; BOFFETTA, Paolo; DUFOUR, Jean-Francois; THUNG, Swan N.; UZILOV, Andrew; CARRILHO, Flair Jose; CHANG, Charissa; SIA, Daniela; LLOVET, Josep M.
  • conferenceObject
    LISTING, DROPOUT AND TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA IN LATIN AMERICA: UNEXPECTED AND PREVIOUSLY NOT REPORTED RESULTS
    (2019) PINERO, Federico; BOIN, Ilka; CHAGAS, Aline; QUINONEZ, Emilio; MARCIANO, Sebastian; VILATOBA, Mario; VARON, Adriana; MCCORMACK, Lucas; DUQUE, Sergio; LIMA, Agnaldo Soares; MENENDEZ, Josemaria; PADILLA, Martin; PONIACHIK, Jaime; ZAPATA, Rodrigo; MARASCHIO, Martin; MENENDE, Ricardo Chong; MUNHOZ, Linda; ARUFE, Diego; FIGUEROA, Rodrigo; CAMPANA, Ariel Gonzalez; PERALES, Simone Reges; MACCALI, Claudia; SANDOVAL, Rodrigo Vergara; BERMUDEZ, Carla; SANTOS, Luiza; BALMER, Matias; ARENAS, Isabel; GERONA, Solange; HENRIQUEZ, Victor; GINESTA, Alexandra; BARRABINO, Martin; RAFFA, Pia; GADANO, Adrian; MATTERA, Juan; ATAIDE, Elaine Cristina; CARRILHO, Flair; SILVA, Marcelo